Horizon Pharma, Inc.
HZNP today announced that the United States Food and Drug
Administration has approved the use of Sanofi's manufacturing site in
Compiegne, France to manufacture DUEXIS(R) (ibuprofen/famotidine), a
proprietary single-tablet combination of ibuprofen (800 mg) and
famotidine (26.6 mg). Valeant Pharmaceuticals' manufacturing site in
Laval, Quebec, previously owned and operated by Sanofi, serves as the
primary commercial manufacturing site for DUEXIS.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in